Tag: ladiratuzumab vedotin

Seattle Genetics signs $4.4bn worth oncology deals with Merck

pharmanewsdaily- September 14, 2020

US biotech company Seattle Genetics has secured deals worth up to $4.4 billion with Merck, that include two new strategic oncology collaborations. The two major ... Read More